Commitments and Contingencies (Details) (USD $)
In Millions, unless otherwise specified |
1 Months Ended | 12 Months Ended | 0 Months Ended | |
---|---|---|---|---|
Jul. 31, 2012
claim
|
Dec. 31, 2014
|
May 06, 2013
Suit
|
Dec. 31, 2013
|
|
Loss Contingencies [Line Items] | ||||
Number of claims included in post-payment audit | 183 | |||
Purchase Obligation | $ 14.7 | |||
Business Acquisition, Contingent Consideration [Line Items] | ||||
Contingent consideration | 71.6 | 71.6 | ||
Accrued Liabilities | ||||
Business Acquisition, Contingent Consideration [Line Items] | ||||
Contingent consideration | 27.4 | 28.0 | ||
Other Noncurrent Liabilities | ||||
Business Acquisition, Contingent Consideration [Line Items] | ||||
Contingent consideration | 44.2 | 43.6 | ||
Merck | ||||
Business Acquisition, Contingent Consideration [Line Items] | ||||
Additional milestone payment to Merck | $ 25.0 | |||
Pending Litigation | PROLOR Biotech, Inc. Shareholders' Litigation | ||||
Loss Contingencies [Line Items] | ||||
Number of putative class action suits filed | 5 |